Breaking News Instant updates and real-time market news.

SLDB

Solid Biosciences

$5.96

-2.9 (-32.73%)

, SHOP

Shopify

$242.78

-7.96 (-3.17%)

10:06
05/14/19
05/14
10:06
05/14/19
10:06

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Solid Biosciences (SLDB) downgraded to Underperform from Neutral at Credit Suisse, to Sell from Neutral at Goldman Sachs, and to Neutral from Buy at Chardan. 2. Shopify (SHOP) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Essex citing his view that the stock is not deserving of the same multiple as high-growth U.S. 3. Deere (DE) downgraded to Underweight from Neutral at JPMorgan with analyst Ann Duignan saying she sees "rapidly deteriorating" fundamentals in U.S. agriculture. 4. G-III Apparel (GIII) and Steven Madden (SHOO) downgraded to Neutral from Overweight at Piper Jaffray. 5. Insys Therapeutics (INSY) downgraded to Neutral from Buy at Janney Montgomery Scott. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

SLDB

Solid Biosciences

$5.96

-2.9 (-32.73%)

SHOP

Shopify

$242.78

-7.96 (-3.17%)

DE

Deere

$146.73

0.38 (0.26%)

GIII

G-III Apparel

$32.19

-1.83 (-5.38%)

SHOO

Steven Madden

$31.02

-0.75 (-2.36%)

INSY

Insys Therapeutics

$0.90

-0.0503 (-5.29%)

  • 17

    May

  • 24

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 13

    Jun

  • 13

    Jun

  • 09

    Jul

  • 17

    Jul

  • 05

    Sep

SLDB Solid Biosciences
$5.96

-2.9 (-32.73%)

05/14/19
CHDN
05/14/19
DOWNGRADE
CHDN
Neutral
Solid Biosciences downgraded to Neutral from Buy at Chardan
05/14/19
05/14/19
DOWNGRADE
Target $6

Underperform
Solid Biosciences downgraded to Underperform at Credit Suisse
As previously reported, Credit Suisse analyst Martin Auster (SLDB) downgraded Solid Biosciences to Underperform from Neutral as he sees enrollment challenges and pressured timelines ahead. Earlier this year, Solid presented underwhelming initial microdystrophin data for the three patients at the low dose, necessitating dose escalation from 5E13 vg/kg to 2E14 vg/kg, he notes. With another treatment-related SAE, the analyst expects enrollment at this high dose may prove challenging, and notes that while improved efficacy at the higher dose could offset AE issues, promising initial data from Sarepta (SRPT) and positive commentary from Pfizer (PFE) on its Gene Tx program limit upside. Auster also lowered his price target on Solid's shares to $6 from $7.
05/14/19
GSCO
05/14/19
DOWNGRADE
Target $4
GSCO
Sell
Solid Biosciences downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Solid Biosciences (SLDB) to Sell from Neutral after the company disclosed additional safety events with the first patient treated at the new high dose in the Phase 1/2 micro-dystrophin gene therapy study in Duchenne muscular dystrophy. Richter, who noted that he has previously expressed concern regarding a higher SGT-001 dose given safety events at the low dose, sees continued risk with the SGT-001 program as the trial continues to enroll, he tells investors. The analyst, who views SGT-001 as "suboptimal" versus competitor Sarepta's (SRPT) gene therapy, cut his price target on Solid shares to $4 from $5.
05/14/19
FBCO
05/14/19
DOWNGRADE
FBCO
Underperform
Solid Biosciences downgraded to Underperform from Neutral at Credit Suisse
SHOP Shopify
$242.78

-7.96 (-3.17%)

05/14/19
MSCO
05/14/19
DOWNGRADE
MSCO
Underweight
Shopify downgraded to Underweight from Equal Weight at Morgan Stanley
05/14/19
MSCO
05/14/19
DOWNGRADE
Target $209
MSCO
Underweight
Morgan Stanley says Shopify model overvalued, downgrades to Underweight
Morgan Stanley analyst Brian Essex downgraded Shopify to Underweight from Equal Weight, citing his view that the stock is not deserving of the same multiple as high-growth U.S. Software-as-a-Service companies as less than half of Shopify's revenue comes from subscriptions. Most of Shopify's revenue is transaction-based and its mix is shifting increasingly toward transaction-based revenue, said Essex, who adds that he thinks investors are overpaying for Shopify's Merchant Solutions business at the stock's current valuation. Essex raised his price target on Shopify shares to $209 from $173, however, as he changed his valuation framework to sum-of-the-parts from discounted cash flow.
05/14/19
BARD
05/14/19
NO CHANGE
Target $269
BARD
Outperform
Baird reiterates Outperform on Shopify following management meetings
After hosting "well-attended" investor meetings with Shopify management, Baird analyst Colin Sebastian reiterates an Outperform rating on the shares with a $269 price target. Shopify continues to benefit from positive network effects, driven by data aggregated on the platform that enables continuous improvement of services plus the addition of new services, Sebastian tells investors in a research note. He points out that management highlighted stable cohort revenue trends, a large and increasing total addressable market, and robust product development. Sebastian says the meetings helped reinforce his view that Shopify is building a "sustainable and differentiated high-value e-commerce platform."
05/13/19
05/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) and Titan Machinery (TITN) downgraded to Neutral from Outperform at Baird. 2. Boot Barn (BOOT) downgraded to Hold from Buy at Pivotal Research with analyst Mitch Kummetz saying he sees a less favorable risk/reward at current share levels heading into the company's results on May 16. He does not see enough room for upside to his estimates, mainly because he believes oil and gas employment is becoming a "diminishing tailwind." 3. Shopify (SHOP) downgraded to Neutral from Buy at Guggenheim with analyst Ken Wong saying he sees upside potential as limited given the stock's current valuation, which he notes has now passed previous peak levels. 4. ADT Inc. (ADT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Toni Kaplan saying she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. 5. 51job (JOBS) downgraded to Neutral from Buy at Citi with analyst Alicia Yap saying she believes weakening operating metrics, such as a faster rate of decline for active employer count and slower rate of growth of ARPU, may be signals of challenges for online recruitment revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DE Deere
$146.73

0.38 (0.26%)

05/14/19
JPMS
05/14/19
UPGRADE
Target $77
JPMS
Overweight
Agco upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Ann Duignan upgraded Agco (AGCO) to Overweight from Neutral and raised her price target for the shares to $77 from $66. The analyst coupled the upgrade with a downgrade of Deere (DE) to Underweight from Neutral. Given Agco's limited exposure to the U.S. row crop sector, the recent sell-off in the shares is overdone, Duignan tells investors in a research note. She sees a good entry point at current share levels.
05/14/19
JPMS
05/14/19
DOWNGRADE
Target $132
JPMS
Underweight
Deere downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Ann Duignan downgraded Deere (DE) to Underweight from Neutral and lowered her price target for the shares to $132 from $154. The analyst coupled the downgrade with an upgrade of Agco (AGCO) to Overweight from Neutral. The analyst sees "rapidly deteriorating" fundamentals in U.S. agriculture. Beyond tariffs, Chinese import demand for soybeans is likely to decline significantly as it deals with a ~30% reduction in its hog herd following the outbreak of African swine fever, Duignan tells investors in a research note. Further, Brazil and Argentina combined have produced close to record soybean and corn crops this season, while U.S. dollar strength remains a headwind for U.S. competitiveness on the global market, adds the analyst. She sees a "perfect storm" for U.S. farmers and believes the fundamentals for Deere are now skewed to the downside.
05/13/19
BARD
05/13/19
DOWNGRADE
BARD
Neutral
Baird downgrades Deere, Titan to Neutral on eroding farmer sentiment
As previously reported, Baird analyst Mig Dobre downgraded Deere (DE) and Titan Machinery (TITN), both to Neutral from Outperform, telling investors that large Ag equipment demand is increasingly at risk as farmer sentiment and grain prices deteriorate amid the drawn out trade war. While Ag inventories at dealers has risen, posing an additional risk, construction equipment growth is moderating, noted Dobre, who lowered his price target on Deere to $150 from $166 and cut his price target on Titan shares to $18 from $26.
GIII G-III Apparel
$32.19

-1.83 (-5.38%)

05/14/19
PIPR
05/14/19
DOWNGRADE
Target $32
PIPR
Neutral
Steven Madden downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Erinn Murphy downgraded Steven Madden (SHOO) to Neutral from Overweight and lowered her price target for the shares to $32 from $38. The company produces a large amount of its goods in China, Murphy tells investors in a research note. The analyst reduced her estimates based on the existing tariffs in place, which she sees impacting Steven Madden's second half earnings. The company's exposure to China and the recently proposed tariffs to the apparel/footwear categories will weigh on its multiple, says Murphy. The analyst also downgraded G-III Apparel (GIII) this morning for a similar rationale.
05/14/19
PIPR
05/14/19
DOWNGRADE
Target $35
PIPR
Neutral
G-III Apparel downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Erinn Murphy downgraded G-III Apparel to Neutral from Overweight and lowered her price target for the shares to $35 from $43. The company produces a large amount of its goods in China, Murphy tells investors in a research note. The analyst reduced her estimates based on existing tariffs in place, which she sees impacting G-III Apparel's second half earnings. The company's exposure to China and the recently proposed tariffs to the apparel/footwear categories will weigh on its multiple, says Murphy.
03/22/19
NEED
03/22/19
NO CHANGE
Target $55
NEED
Buy
G-III Apparel price target raised to $55 from $50 at Needham
Needham analyst Rick Patel raised his price target on G-III Apparel to $55 and kept his Buy rating after its "strong" Q4 sales, stating that the company's 2019 targets now appear to be achievable. The analyst is positive on the management's efforts to reduce expenses in retail, adding that the company's guidance also does not account for new licenses for wholesale or distribution channels that have not yet finalized. Patel further states that his model assumes a "conservative" view of "flattish retail comps" in light of challenging industry trends.
05/14/19
COWN
05/14/19
NO CHANGE
COWN
Skechers, G-III among apparel names with outsized tariff risk, says Cowen
Cowen analyst John Kernan said 34% of apparel and about 70% of footwear imported into the U.S. come from China, adding that 25% tariffs on apparel and footwear will create "major disruption" at a time when companies are already facing accelerating disruption from technology and Amazon (AMZN). The analyst, who thinks diversifying from China sourcing will be slow, said he views Skechers (SKX), G-III Apparel (GIII), Carter's (CRI), PVH Corp. (PVH) and Ralph Lauren (RL) as among the apparel stocks with outsized EPS risk. He added that he thinks companies like Under Armour (UAA), that may have lower than sector average exposure to China sourcing but also have lower EBIT margins, as faced with greater sensitivity to higher cost of goods.
SHOO Steven Madden
$31.02

-0.75 (-2.36%)

01/31/19
01/31/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMC Networks (AMCX) downgraded to Underperform from In-Line at Imperial Capital with analyst David Miller saying he reduced his fiscal 2019 estimates for the company to reflect his expectation of lower scatter effects for The Walking Dead, as well as higher overall production costs. 2. General Dynamics (GD) downgraded to Hold from Buy at Argus with analyst John Eade saying the company's latest results topped consensus, but the growth outlook for 2019 in low single digits was disappointing. 3. Allergan (AGN) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan citing "underwhelming" 2019 guidance and given additional questions he has on the strength of its business. 4. Steven Madden (SHOO) downgraded to Market Perform from Outperform at Telsey Advisory with analyst Dana Telsey saying while Steven Madden has a lot to like, external factors, such as tariffs and a wholesale channel that has a "more muted tone" entering 2019 as compared to 2018, may weigh on the stock price. 5. PayPal (PYPL) downgraded to Hold from Buy at DZ Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/19/19
LOOP
02/19/19
NO CHANGE
Target $38
LOOP
Buy
Steven Madden price target raised to $38 from $36 at Loop Capital
Loop Capital analyst Laura Champine raised her price target on Steven Madden to $38 and kept her Buy rating, citing the benefits of its "rapid supply chain in on-trend fashion" at its stores and higher growth expectations of its wholesale sales. The analyst expects the company to gain market share with the largest footwear outlets and believes its competitive position with healthy retailers is improving in spite of the latest store closure announcement by Payless, adding that investor concerns about tariff headwinds for the company are also "overblown".
02/14/19
ADAM
02/14/19
NO CHANGE
Target $39
ADAM
Buy
Steven Madden weakness would be buying opportunity, says Canaccord
Canaccord analyst Camilo Lyon removed Payless from his Steven Madden estimates in order take a more conservative view on earnings due to the former's potential bankruptcy filing. The analyst believes any impact to the stock should be short-lived, as the company has done well navigating these types of issues in the past and the impact to the stock has rarely lasted longer than a quarter. Lyon reiterated his Buy rating and lowered his price target to $39 from $41 on Steven Madden shares.
INSY Insys Therapeutics
$0.90

-0.0503 (-5.29%)

03/08/19
PIPR
03/08/19
NO CHANGE
Target $4
PIPR
Underweight
Insys unlikely to find buyer for Subsys, says Piper Jaffray
Pressure on Subsys was once again a central theme in Insys Therapeutics' Q4 results, Piper Jaffray analyst David Amsellem tells investors in a post-earnings research note. The analyst says that given the challenging dynamics associated with Subsys, he has a difficult time envisioning a buyer emerging for the product. Amsellem continues to believe there is downside risk associated with Insys Therapeutics shares. He reiterates an Underweight rating on the name with a $4 price target.
05/13/19
PIPR
05/13/19
NO CHANGE
Target $2
PIPR
Underweight
Government's end game may be putting Insys out of business, says Piper Jaffray
Piper Jaffray analyst David Amsellem cut his price target for Insys Therapeutics to $2 from $4 and reiterates an Underweight rating on the shares. The company on Friday night announced that it is facing significant liquidity issues such that it may not be able to continue as a going concern due to estimated liabilities of $240M related to the U.S. Department of Justice investigation and other legal matters, coupled with the continued deterioration of Subsys sales/volumes, Amsellem tells investors in a research note. Perhaps the end game of the federal government is Insys no longer being a going concern, adds the analyst.
03/08/19
CANT
03/08/19
NO CHANGE
Target $9
CANT
Overweight
Insys faces 'pivotal and transformational' year in 2019, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Insys Therapeutics with a $9 price target following the company's Q4 results. The analyst believes 2019 will be a "pivotal and transformational year" for the company. Insys has two potential filings with its spray platform this year, along with two "significant" data readouts from the company's cannabinoids platform, Folkes tells investors in a post-earnings research note titled "CBD Epilepsy Is a Significant Near-Term Catalyst Not to Be Ignored." Data readouts should drive stock momentum, making 2019 the year in which investors are able to return to Insys Therapeutics and appreciate the value that could be unlocked from within the company's spray and cannabinoids pipeline, adds the analyst.
05/14/19
JANY
05/14/19
DOWNGRADE
JANY
Neutral
Insys Therapeutics downgraded to Neutral from Buy at Janney Montgomery Scott

TODAY'S FREE FLY STORIES

TEVA

Teva

$10.86

-0.18 (-1.63%)

12:11
05/26/19
05/26
12:11
05/26/19
12:11
Hot Stocks
Teva reaches $85M agreement with State of Oklahoma »

Teva Pharmaceuticals USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLT

Elbit Systems

$141.85

1.33 (0.95%)

12:08
05/26/19
05/26
12:08
05/26/19
12:08
Hot Stocks
Elbit Systems awarded $127M contract to provide tactical radio system »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ADM

Archer Daniels

$39.17

-0.03 (-0.08%)

12:05
05/26/19
05/26
12:05
05/26/19
12:05
Hot Stocks
Archer Daniels expands recall of Baker's Corner All Purpose Flour 5lb bags »

ADM Milling is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.